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ABSTRACT
Background: Low-birth-weight infants may have impaired zinc
status, but little is known about the effect of zinc supplementation.
Objective: The objective was to investigate the effect of daily zinc
supplementation on morbidity and anthropometric status in hospital-
born, low-birth-weight infants.
Design: In a double-blind, randomized, placebo-controlled trial,
2052 hospital-born term infants with a birth weight 2500 g were
randomly assigned to receive zinc or placebo. The zinc group re-
ceived elemental zinc: 5 mg/d for those infants between ages 2 wk
and 6 mo and 10 mg/d for those infants aged .6 mo. All-cause
hospitalizations, prevalence of diarrhea, acute lower respiratory
tract infections, visits to health care providers, weights, and lengths
were ascertained at 3, 6, 9, and 12 mo of age.
Results: The supplement was consumed for .85% of the follow-up
period. Mean plasma zinc at 12 mo of age was higher in the zinc
group (100.2 lg/dL) than in the control group (73.3 lg/dL) (differ-
ence in means: 26.9; 95% CI: 19.6, 34.2). The 24-h and 7-d preva-
lence of diarrhea and acute lower respiratory tract infections was
similar at 3, 6, 9, and 12 mo. Care-seeking for illness was signifi-
cantly lower in the zinc group (difference in proportions:25.7; 95%
CI: 29.9, 21.4; P , 0.05) at 9 mo. The numbers of hospitaliza-
tions, weights, and lengths were all similar at all 4 assessments.
Conclusion: Hospital-born, term, low-birth-weight infants do not
seem to benefit substantially from zinc supplementation that meets
the Recommended Dietary Allowance for zinc in terms of morbidity
or physical growth during infancy in this setting. This trial was
registered at www.clinicaltrials.gov as NCT00272142. Am J
Clin Nutr 2009;90:385–91.
INTRODUCTION
Zinc is a micronutrient of biological and public health im-
portance because it is essential for protein synthesis and nucleic
acid metabolism. Zinc deficiency impairs innate and acquired
immunity (1). Supplementation trials with zinc in children aged
6 mo to 3 y of age have shown significant reduction in diarrheal
and lower respiratory tract infections (2–5). However, there are
few such supplementation trials in low-birth-weight infants (6, 7).
Of the annual 20 million low-birth-weight neonates, ’95%
are born in developing countries (8). Low birth weight is esti-
mated to be an underlying risk factor in 70% of perinatal deaths,
90% of neonatal deaths, and 50% of infant deaths (9).
Low birth weight is associated with growth faltering and
substantially increasing risk of severe infection–related mor-
bidity and mortality. Impaired zinc status has been reported in
small-for-date infants (10, 11). Postnatal zinc deficiency has been
attributed to factors such as low body stores, limited capacity to
absorb and retain micronutrients coupled with increased en-
dogenous losses associated with organ immaturity, high nutrient
demand to support catch-up growth, and inadequate intakes
because of exclusive breastfeeding (12). Low concentrations of
zinc in the cord blood of low-birth-weight infants have been
noted in several settings and are correlated with birth weight and
gestation (13). Furthermore, significant reduction in zinc con-
centrations (P , 0.05) during lactation is reported, and it has
been postulated that the amount of zinc provided by breast milk
may be lower than the Recommended Dietary Allowance (RDA)
of zinc (13).
Clinical trials to assess potential benefits of zinc supple-
mentation in early infancy need to be done in hospital-born babies
and in those delivered at home because socioeconomic and di-
etary practices differ. We conducted an individually randomized
placebo-controlled trial to assess efficacy of daily zinc supple-
mentation between 2 to 4 wk and 12 mo of age in hospital-born,
low-birth-weight infants. We hypothesized that hospital-born,
term, low-birth-weight infants were likely to be zinc deficient and
that supplementation with the RDA in the first year of life would
decrease mild and severe diarrhea and acute lower respiratory
tract infections (ALRIs) and improve physical growth compared
with a group administered a placebo.
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SUBJECTS AND METHODS
A double-blind, randomized, placebo-controlled trial was
conducted between January 2005 and August 2007. The setting
was urban low to middle socioeconomic neighborhoods in New
Delhi, India. Data indicate that childhood undernutrition and
micronutrient deficiency are common in children residing in
similar settings (2, 3, 7). The burden of childhood diarrhea and
respiratory infections is high (2, 14).
Clearances were obtained from the ethics committee of the All
India Institute of Medical Sciences, the World Health Organi-
zation review committee, and the Society for Applied Studies.
Study participants were term infants (gestational age.37 wk)
with a birth weight of 2500 g born in the Kasturba and Hindu
Rao Hospitals. These are government institutions that provide
treatment free of cost to the population. Infants in the in-
tervention group received elemental zinc, 5 mg daily for those
aged 6 mo and 10 mg thereafter, from the day of enrollment
(2–4 wk age) until the age of 12 mo. Infants in the control group
received placebo daily for the same period.
Consent was sought from community leaders in the study area.
Flyers were distributed to raise community awareness about the
study.Written consent (or thumb imprints for thosewho could not
write) was obtained from caregivers of enrolled infants, and
a copy of the consent form was left with the family.
Trial size
Estimates for hospitalization rates for infants in the control
group were obtained from an earlier trial (15); the all-cause
hospitalization rate was 207/1000 child-years of follow-up, and
hospitalization rates due to diarrhea and ALRI were 9/1000 child-
years and 114/1000 child-years, respectively. To detect a 25%
reduction in all-cause hospitalizations, a 35% reduction in
hospitalizations for respiratory illness, and a 40% reduction in
hospitalizations due to diarrhea, a total of 2000 infants were
required after an inflation of 10% for attrition rates. The value of
a was 0.05 (95% CI) and that of b was 0.1 (90% power) for
these calculations.
Randomization and blinding
A simple randomization scheme in permuted blocks of fixed
length of 20 was used to guard against possible seasonal var-
iations of diarrheal morbidity. The randomization list and the
labeling of the supplement with a subject identification number
were done by a statistician not involved with the study.
Supplement
The supplement was in the form of dispersible tablets pack-
aged in strips containing 15 tablets each. Monthly supplies of
tablets were given to the caregiver to be stored in plastic boxes
with tight lids to ensure inaccessibility by young children. The
tablets for the intervention group contained 5 mg of elemental
zinc as zinc sulfate. The placebo tablets were similar in ap-
pearance and taste. Tablets were manufactured by Nutriset
(Malaunay, France). Caregivers were asked to administer one
tablet dissolved in 5 mL of expressed breast milk to infants aged
6 mo. Older infants received 2 tablets daily dissolved in breast
milk or water.
Enrollment procedures
Study supervisors identified new births in the 2 hospitals daily.
Caregivers of term infants living 10 km of the hospital were
informed about the study and, if they were willing to participate,
weight and length measurements were obtained. Supervisors and
supplement dispensers visited homes of potentially eligible in-
fants when they were aged 2–4 wk and enrolled them into the
study if written consent was given. In addition to the baseline
characteristics, mothers of enrolled infants were queried for
having been diagnosed with diabetes, hypertension, antepartum
hemorrhage, history of convulsions, or severe pallor during
pregnancy. Infants with severe malnutrition, twins, or infants
who had serious illnesses requiring hospitalization were ex-
cluded. If there was more than one eligible infant in a household,
only one was enrolled in the trial. The procedure for adminis-
tration of the supplement was shown to caregivers.
Co-interventions
Immunizations were provided according to the national pro-
gram. From 2 mo of age, infants received iron (Tonoferron; East
India Pharmaceutical Works Ltd, Kolkata, India)—with each
milliliter containing colloidal elemental iron, lysine hydrochlo-
ride, vitamin B-12, and folic acid—and multivitamin drops
(Visyneral; USV Ltd, Mumbai, India)—with each milliliter
containing vitamin A, vitamin B-6, vitamin C, vitamin D2, thi-
amine, riboflavin, niacinamide, D-panthenol, biotin, and toco-
pheryl acetate and excluded zinc according to hospital policy for
infants born at low birth weight. Caregivers were advised not to
co-administer iron and multivitamin supplements with zinc and
to administer the drops to infants in evenings and the zinc
supplement in mornings (16, 17). Enrolled infants had access to
the services of both hospitals in addition to several other gov-
ernment and private health care facilities in the area.
Measurement of outcomes
Research assistants visited homes every 3 mo, and supplement
dispensersvisitedmonthlytodeliverthetabletsanddocumentintake
for thepreviousmonth throughexaminationof the tablet stripandby
querying the mother. At 12 mo of age, a food-frequency ques-
tionnaire was also administered at the home visits to obtain in-
formation about the types of foods consumed by the infants. Infants
werecalled to thehospital for blood sampling at the endof the study.
Infants were home visited at ages 3, 6, 9 and 12 mo by research
assistants. Caregivers were queried about recent (24-h, 7-d, and
1-mo) diarrheal and respiratory morbidity, care-seeking and
hospitalizations, and clinical examinations. If an enrolled infant
died during the follow-up period, a verbal autopsy (18) was
conducted by a trained interviewer.
Anthropometric measurements and zinc assays
Weights and lengthsweremeasured at homeat 3, 6, 9, and12mo
of age. The portable weighing scale weighed to the nearest 100 g
(Seca,SalterScales,Hamburg,Germany) and lengthmeasurement
boards manufactured locally measured to the nearest 0.1 cm.
Blood samples were obtained in 15% of the randomly selected
infants at baseline and at 12mo of age. A 5-mLnonfasting, venous
blood sample was drawn in zinc-free, heparinized polypropylene
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tubes(Sarstedt,Numbrecht,Germany).Aftercentrifugation(447·
g, 10 min), plasma was transferred to zinc-free polypropylene
vials (Eppendorf, Hinz, Germany) and stored at 220C until
analysis. Zinc assays were performed by using standard flame
furnace atomic absorption spectrophotometer technique (GBC
Avanta, Dandenong, Australia). Seronorm was used as the refer-
ence standard (Sero AS, Billingstad, Norway) in every batch of 20
samples. Hemoglobin concentration and hematocrit were esti-
mated from capillary blood by using HemoCue AB 201 (Angle-
holm, Sweden) (19).
Training and standardization
Teams were trained in obtaining consent, filling out forms,
answering families’ queries, supplement administration, and
referral. Standardization exercises for inter- and intraobserver
variability in weights and lengths were conducted in which each
child was measured twice (10 sets of 10 infants each, aged,1 y).
Exercises ceased only when all research assistants obtained
identical readings in both their weight measurements on a child
and were in perfect agreement with the group mean, ie, the
arithmetic mean of the measurement obtained for a set of 10
infants by all research assistants (20). For length, a difference of
0.5 cm between the readings of a research assistant and the
group mean was considered acceptable. The accuracy of
weighing scales was checked daily against known standard
weights and the accuracy of infantometers was checked by using
standard steel rods.
Definitions used
Diarrhea was defined as the passage of 3 loose or watery
stools in a 24-h period. ALRI was defined the presence of cough
or difficult breathing associated with a respiratory rate 50
breaths/min (21). Severe diarrhea was defined as the presence of
diarrhea in the previous 24 h with the maximum number of loose
or watery stools greater than the median frequency of all di-
arrheal stools in the previous 24 h, or presence of signs of de-
hydration in the previous 24 h. Severe ALRI was defined as the
presence of ALRI in the previous 24 h associated with one or
more of the following: nasal flaring, grunting or stridor, lower
chest indrawing, or an infant drinking poorly. Hospitalization
was defined as admission to an inpatient facility of 6 h dura-
tion or as an inpatient death irrespective of duration of admis-
sion. For the purpose of analysis, hospitalizations of the same
infant were separated by a 2-wk time frame.
Data management and analysis
Forms were designed in FoxPro for Windows version 6
(Microsoft Corporation, Redmond, WA), and range and con-
sistency checks were programmed during the designing of the
database. Double data entry was followed by validation and
merging of clean data into a master database. Analysis was
conducted by using Stata software version 8.2 (Stata Corp LP,
College Station, TX).
Characteristics of all infantswhowere randomly assigned to the
2 groups were displayed in the baseline table. For the 3 monthly
visits, infants were included in the analysis if the home visit was
conducted within the predefined time frame. The maximum delay
or advance of measurement allowed was 10% of the child age at
each visit (ie,69,618,627, and636 d for the visits at ages 3, 6,
9, and 12 mo, respectively). Hospitalization data were included
for the period that an infant was available for follow-up.
The proportion of children whowere wasted (weight for height
2 SD), stunted (height for age 2 SD), or underweight (weight
FIGURE 1. Trial profile.
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for age 2 SD) according to the World Health Organization Child
Growth Standards median at different ages was estimated (22).
The differences in means or proportions and their 95% CIs
were estimated for all outcomes. Categorical outcomes were
compared by using the chi-square test for proportions or chi-
square for trend for multiple strata.
RESULTS
A total of 9725 infants were identified 24 h of birth in 2
hospitals. Of these, 2504 were screened between 2 and 4 wk of
age. Of the 2504 infants screened, 2052 (81.9%) were enrolled,
1026 each in the zinc and placebo groups. Of all enrolled in-
fants, .92% were available for each of the visits at ages 3, 6, 9,
and 12 mo within predefined time frames (Figure 1). Of visits
not made, the primary reason was that families were away. The
numbers of families whowithdrew consent during the 1-y follow-
up period were 7 and 10: 4 and 6 infants at the 3-mo visit and an
additional 3 and 4 infants at the 12-movisit in the zinc and placebo
groups, respectively.
The mean age at enrollment was 15 d, and ’50% of the
enrolled infants were male (Table 1). Infants in the zinc and
placebo groups were similar for several infant and family
characteristics. Ninety-nine percent of enrolled infants were
breastfed. Prevalence of morbidity in the previous 24 h, mean
weights and lengths, and zinc and hemoglobin concentrations in
blood were similar at baseline. Approximately three-fourths of
mothers and four-fifths of fathers were literate (Table 1). The
prevalence of diabetes, hypertension or antepartum hemorrhage,
history of convulsions, or severe pallor as reported by mothers
during the antenatal period was similar in the 2 groups (data not
shown, P . 0.05).
The total days of follow-up were 355,460 d and 355,989 d in
the zinc and placebo groups, respectively. Infants in the zinc
group were supplemented on 85.8% of the days and those in the
placebo group for 86.1% of the days. The common reasons for
nonadministration of the supplement were that the families were
temporarily away or the mother forgot; ,1% of mothers cited
unwillingness of the infant to take the supplement as a reason.
The prevalence of vomiting in the previous 24 h at different
ages, comparing zinc with placebo groups, was 7.3% compared
with 6.9% at 3 mo, 5.3% compared with 3.9% at 6 mo, 5.6%
compared with 5.4% at 9 mo, and 3.7% compared with 4.5% at
12 mo (P . 0.05 for all comparisons).
The mean plasma zinc concentrations were higher in the zinc
group infants 12 mo postsupplementation than in the placebo
group infants (100.2 compared with 73.3 lg/dL; difference in
means: 26.9 lg/dL; 95% CI: 19.6, 34.2 lg/dL). The proportion
of infants with zinc deficiency using a cutoff of ,60 lg/L was
also significantly lower in the zinc group (difference in pro-
portions: 211.8%; 95% CI: 220%, 23.4%; P , 0.005). Zinc
supplementation had no effect on iron status; hemoglobin con-
centrations and hematocrit were similar in infants in the 2
groups 12 mo postsupplementation (Table 2).
The prevalence of diarrhea and ALRI in the previous 24 h and
7 d was similar at the 3-, 6-, 9-, and 12-mo visits in the zinc and
placebo groups. The prevalence of severe diarrhea and ALRI in
the previous 24 h at each of these visits also was similar (Table
3). The proportion of infants who sought care for any illness,
diarrhea, or pneumonia in the 1 mo preceding the home visit was
similar at the 3-, 6-, and 12-mo visits. Care-seeking rates for
illness were significantly lower (difference in proportions: 25.7;
95% CI: 29.9, 21.4; P , 0.05) at the 9-mo visit in infants who
had zinc supplements than in those in the placebo group. The
proportion of infants who were never hospitalized or hospital-
ized once, twice, or 3 times also was similar (chi-square for
TABLE 1
Baseline characteristics of families and infants 2–4 wk of age enrolled in
the zinc and placebo groups1
Characteristics
Zinc
(n = 1026)
Placebo
(n = 1026)
Age (d) at enrollment 15.3 6 2.12 15.3 6 2.1
Male infants [n (%)] 463 (45.1) 448 (43.7)
Breastfed [n (%)] 1020 (99.4) 1020 (99.4)
24-h morbidity [n (%)]
Diarrhea3 47 (4.6) 41 (4.0)
Acute lower respiratory tract
infection4
231 (22.5) 200 (19.5)
Fever 22 (2.1) 23 (2.2)
Literate mothers [n (%)] 789 (76.9) 763 (74.4)
Literate fathers [n (%)] 848 (82.7) 864 (84.2)
Total no. of family members 7.0 6 3.5 6.8 6 3.3
Family income (rupees/mo) 4000 (2700,
6000)5
4000 (2500,
6000)
Weight (kg) 2.3 6 0.2 2.3 6 0.2
Length (cm) 46.0 6 1.3 46.1 6 1.3
Plasma zinc (lg/dL)6 63.4 6 20.9 64.7 6 30.1
,60 lg/dL [n (%)] 92 (50.2) 107 (56.8)
,55 lg/dL [n (%)] 66 (36.1) 82 (42.9)
Hemoglobin (g/L)7 15.9 6 2.4 15.9 6 2.4
Hematocrit (%)7 49.9 6 7.8 49.3 6 7.5
1 No differences between the 2 groups were statistically significant
(t test for comparison of means and chi-square test for proportions).
2 Mean 6 SD (all such values).
3 Passage of 3 loose or watery stools with recent change in frequency
and character of stools.
4 Cough or difficult breathing and fast breathing.
5 Median; interquartile range in parentheses (all such values).
6 n = 183 and 191 for the zinc and placebo groups, respectively.
7 n = 182 and 193 for the zinc and placebo groups, respectively.
TABLE 2
Effect of zinc supplementation on plasma zinc hemoglobin and hematocrit
concentrations at 12 mo of age in the zinc and placebo groups
Zinc
(n = 151)
Placebo
(n = 168)
Difference in
means/proportions1
Plasma zinc (lg/dL) 100.2 6 41.92 73.3 6 22.5 26.9 (19.6, 34.2)3
,60 lg/dL [n (%)] 19 (12.6) 41 (24.4) 211.8 (220, 23.4)4
,55 lg/dL [n (%)] 13 (8.6) 24 (14.3) 25.7 (212.6, 1.3)
Hemoglobin (g/L)5 9.4 6 1.4 9.6 6 1.4 20.23 (20.54, 0.07)
,10 g/L [n (%)] 102 (66.7) 93 (54.7) 12.0 (1.4, 22.5)6
Hematocrit (%)5 32.7 (4.2) 33.1 (4.3) 20.41 (21.34, 0.52)
,33% [n (%)] 65 (42.5) 71 (41.8) 0.7 (210, 11.5)
1 Derived by using a t test for comparison of means and test of pro-
portion for comparison of difference in proportions; 95% CI in parentheses
(P . 0.05 unless noted otherwise).
2 Mean 6 SD (all such values).
3 P , 0.0001.
4 P , 0.005.
5 n = 153 and 170 for the zinc and placebo groups, respectively.
6 P , 0.003.
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trend: P = 0.72) in the 2 groups (Table 4).There were 21 deaths
in the zinc group and 19 in the placebo group (P . 0.05).
The mean (6SD) weights and lengths at 3, 6, 9, and 12 mo in
the zinc and placebo infants are shown in Figure 2. The pro-
portions of infants wasted, stunted, and underweight in the zinc
compared with placebo groups were 14.9% compared with
16.1%, 43.3% compared with 42%, and 59.0% compared with
56.7% at 3 mo; 16.9% compared with 18.6%, 38.3% compared
with 35.5%, and 46.5% compared with 45.8% at 6 mo; 19.1%
compared with 19.2%, 45.3% compared with 42.9%, and 48.2%
compared with 46.4% at 9 mo; and 23.9% compared with
23.8%, 53.8% compared with 50.1%, and 51.9% compared with
51.1% at 12 mo, respectively. All comparisons were statistically
not significant (P . 0.05).
Dietary recalls at 12 mo of age in enrolled infants revealed that
cereals were consumed daily in 75% of infants and legumes daily
in 15% of infants and 2 to 4 times/wk by an additional 41% of
infants. Animal milk or other milk products were consumed daily
by 66% of infants. Egg, lamb, or chicken was fed to 45% of
infants 1 time/wk; of these infants, 21% received these foods
2 to 4 times/wk.
DISCUSSION
The main findings of the study are that zinc supplementation at
one RDA started between 2 and 4 wk of age and given until the
age of 12 mo in hospital-born, low-birth-weight infants had no
significant effect on diarrheal or respiratory morbidity or on
anthropometric status at 3, 6, 9, and 12 mo of age. These findings
based on hospital-born babies in an urban setting may not
necessarily apply to infants at similar ages delivered at home
under different socioeconomic circumstances, in those following
different dietary practices, or in those residing in rural areas. The
TABLE 3
Diarrhea and respiratory morbidity at different ages in the zinc and placebo
groups1
Zinc
(n = 976)
Placebo
(n = 947)
Difference in
proportions2
Age 3 mo, past 24 h
Diarrhea 183 (18.8)3 193 (20.4) 21.6 (25.2, 1.9)
Severe diarrhea 91 (9.3) 80 (8.5) 0.9 (21.7, 3.4)
ALRI 117 (12.0) 113 (11.9) 0.1 (22.8, 2.9)
Severe ALRI 41 (4.2) 48 (5.1) 20.9 (22.7, 1.0)
Age 3 mo, past 7 d
Diarrhea 306 (31.4) 321 (33.9) 22.5 (26.7, 1.6)
ALRI 139 (14.2) 137 (14.5) 20.2 (23.4, 2.9)
Age 6 mo, past 24 h4
Diarrhea 145 (15.0) 153 (15.9) 20.9 (24.2, 2.3)
Severe diarrhea 72 (7.4) 72 (7.5) 20.1 (22.4, 2.3)
ALRI 98 (10.2) 78 (8.1) 2.0 (20.6, 4.6)
Severe ALRI 40 (4.2) 26 (2.7) 1.4 (20.2, 3.1)
Age 6 mo, past 7 d
Diarrhea 283 (29.3) 264 (27.6) 1.8 (22.3, 5.8)
ALRI 122 (12.6) 89 (9.3) 3.4 (0.6, 6.1)
Age 9 mo, past 24 h5
Diarrhea 129 (13.3) 152 (15.9) 22.6 (25.8, 0.5)
Severe diarrhea 55 (5.7) 59 (6.2) 20.5 (22.6, 1.6)
ALRI 49 (5.1) 51 (5.4) 20.3 (22.3, 1.7)
Severe ALRI 15 (1.6) 14 (1.5) 0.1 (21.0, 1.2)
Age 9 mo, past 7 d5
Diarrhea 244 (25.2) 271 (28.5) 23.3 (27.2, 0.7)
ALRI 59 (6.1) 57 (6.0) 0.1 (22.1, 2.2)
Age 12 mo, past 24 h6
Diarrhea 117 (12.2) 118 (12.4) 20.2 (23.1, 2.8)
Severe diarrhea 51 (5.3) 50 (5.2) 0.1 (21.9, 2.1)
ALRI 34 (3.6) 26 (2.7) 0.8 (20.7, 2.4)
Severe ALRI 13 (1.4) 9 (0.9) 0.4 (20.5, 1.4)
Age 12 mo, past 7 d6
Diarrhea 227 (23.7) 222 (23.3) 0.4 (23.5, 4.2)
ALRI 37 (3.9) 28 (2.9) 0.9 (20.7, 2.5)
1 ALRI, acute lower respiratory tract infection.
2 Derived by using a test of proportions for comparison of difference in
proportions; 95% CI in parentheses (P . 0.05 for all comparisons).
3 n; percentage in parentheses (all such values).
4 n = 965 and 958 for the zinc and placebo groups, respectively.
5 n = 967 and 951 for the zinc and placebo groups, respectively.
6 n = 959 and 952 for the zinc and placebo groups, respectively.
TABLE 4
Treatment-seeking and hospitalization rates in the zinc-supplemented and
control groups1
Zinc Placebo
Difference in
proportions2
Sought treatment 1
time in the past
month for the
following illnesses
Age 3 mo3
Any 538 (55.1)4 524 (55.3) 20.2 (24.7, 4.2)
Diarrhea 194 (36.1) 201 (38.4) 22.3 (28.1, 3.5)
ALRI 90 (16.7) 89 (17.0) 20.3 (24.8, 4.2)
Age 6 mo5
Any 612 (63.4) 595 (62.1) 1.3 (23.0, 5.6)
Diarrhea 232 (37.9) 238 (40.0) 22.1 (27.6, 3.4)
ALRI 139 (22.7) 115 (19.3) 3.4 (21.2, 7.9)
Age 9 mo6
Any 595 (61.5) 639 (67.2) 25.7 (29.9, 21.4)7
Diarrhea 246 (41.3) 264 (41.3) 0.0 (25.5, 5.5)
ALRI 118 (19.8) 122 (19.1) 0.7 (23.7, 5.2)
Age 12 mo8
Any 567 (59.1) 555 (58.3) 0.8 (23.6, 5.2)
Diarrhea 235 (41.5) 235 (42.3) 20.9 (26.7, 4.9)
ALRI 79 (13.9) 83 (14.9) 21.0 (25.1, 3.1)
Infants hospitalized9
Never 837 (81.9) 849 (83.2)
Once 160 (15.6) 147 (14.4)
Twice 22 (2.1) 19 (1.9)
Three or more times 3 (0.3) 5 (0.5)
Hospitalizations
(no./1000 child-years
of follow-up)
189.9 175.3 1.10 (0.87, 1.39)10
1 ALRI, acute lower respiratory tract infection.
2 Derived by using a test of proportions for comparison of difference in
proportions; 95% CI in parentheses (P . 0.05 for all comparisons unless
noted otherwise).
3 n = 976 and 947 for the zinc and placebo groups, respectively.
4 n; percentage in parentheses (all such values).
5 n = 965 and 958 for the zinc and placebo groups, respectively.
6 n = 967 and 951 for the zinc and placebo groups, respectively.
7 P , 0.05.
8 n = 959 and 952 for the zinc and placebo groups, respectively.
9 n = 1022 and 1020 for the zinc and placebo groups, respectively; P =
0.71 (chi-square test for trend).
10 Odds ratio; 95% CI in parentheses.
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consumption of animal foods, literacy rates of both parents, and
family income in the study subjects was substantially higher than
in other neighboring communities (23).
Although the effect of improved zinc intake in reducing di-
arrheal and respiratory morbidity has been observed in children
aged 6 mo to 3 y, few studies have assessed the effect of zinc
supplementation in the initial 6 mo of life of children who were
born with a low birth weight (4).
Sur et al (6) assessed the effect of zinc sulfate supplementation
(5-mg daily dose) in low-birth-weight infants selected from
a poor urban community during their first year of life and reported
a significant reduction in the incidence of diarrhea. Interestingly,
the effect was observed only at ages when breastfeeding had
declined. In another trial, in which mothers were administered
a zinc supplement or placebo during pregnancy, a significant
reduction in diarrheal morbidity during the first 6 mo of life was
observed in their offspring in the intervention group; this effect
was substantially greater in the low-birth-weight subset (24).
In the only study that measured effect of zinc supplementation
on mortality in neonates who were small for gestational age,
Sazawal et al (7) reported significant reduction in all-cause
mortality in those supplemented daily with zinc; the reduction in
mortality was apparent as early as 4 mo of age.
Thelackofsignificanteffectonmorbidityat9and12moofageis
surprisingbecauseprevious studieshaveshownapositiveeffect (2,
3). A possible reasonmay be that most previous studies used a 20-
mg rather than a 10-mg daily dose of zinc. Furthermore, most
previous trials were community based rather than hospital based,
with possible socioeconomic and dietary differences.
We did not observe any significant effect on weight or length
gain. The findings from the literature on this issue vary. In very-
low-birth-weight infants, Freil et al (25) reported significant
increase in linear growth velocity but not in weight gain. On the
other hand, Sur et al (6) reported significant increases in both
length and weight gain at 12mo of age after zinc supplementation
in low-birth-weight infants. The effect on weight gain became
apparent after 4 mo of age and that in length only at 10 mo of age.
A recent meta-analysis on effect of micronutrients on physical
growth in children aged ,5 y did not report improvement in
linear growth with zinc supplementation (26). The difference
from a previous meta-analysis that reported a positive effect on
linear growth was attributed by the authors to the fact that the
recent trials were done in children with relatively better nutri-
tional status (27).
Factors other than socioeconomic status also need consider-
ation. Noncompliance is unlikely to explain the lack of effect in
the current trial, because .85% of participants reported having
consumed the supplement and the prevalence of zinc deficiency
was 50% lower at 12 mo in the intervention group.
The zinc salts and dosing used in the study were similar to
those used in the study done in Kolkata (6). A notable difference
was that the incidence of diarrheal illness was reported in
Kolkata, whereas diarrhea prevalence was estimated in our study.
Furthermore, although severity parameters used for defining
severe ALRI were similar to those used in earlier studies, the ones
used for diarrhea were less stringent than those used by others.
This difference in severity parameters may be relevant because
zinc supplementation has a greater effect on incidence of severe
diarrhea.
Notably, the studies by Sazawal et al (7) and Sur et al (6),
which showed a positive effect, used liquid formulations com-
pared with the current study, which used tablets. The fact that
plasma zinc concentrations at 12 mo of age were significantly
improved in the intervention group indicates that this is an un-
likely explanation for the differences in results.
In conclusion, although low zinc concentrations were common
in infants born at low birth weight, supplementation with one
RDA did not reduce morbidity or improve physical growth.
Because the socioeconomic status of families enrolled in the trial
was better than that observed in neighboring communities, fur-
ther trials in community settings with varying zinc dosages are
required.
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